Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-02-27
2007-02-27
Nickol, Gary B. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000
Reexamination Certificate
active
10166325
ABSTRACT:
Disclosed are compositions and methods comprising a novel tumor suppressor gene, designated NOEY2, that is expressed in normal ovarian and breast surface epithelial cells but consistently absent or down-regulated in ovarian and breast cancer cells. Disclosed are polynucleotide compositions comprising a NOEY2 gene from mammalian sources, and polypeptides encoded by these nucleic acid sequences. Also disclosed are methods for preparing NOEY2 polypeptides, transformed host cells, and antibodies reactive with NOEY2 polypeptides. In certain embodiments, the invention describes methods for diagnosing and treating cancers, as well as methods for identifying NOEY2-related polynucleotide and polypeptide compositions.
REFERENCES:
patent: 6043088 (2000-03-01), Bookstein et al.
Albanese et al., “Transforming p21rasmutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions,”J. Biol. Chem.,270:23589-23597, 1995.
Bast et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,”New Engl. J. Med.,309:883-887, 1983.
Bast et al., “Malignant transformation of ovarian epithelium,”J. Natl. Cancer Inst.,84:556-558, 1992.
Bast et al., “Reactivity of a monoclonal antibody with human ovarian carcinoma,”J. Clin. Invest.,68:1331-1337, 1981.
Berchuck et al., “Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer,”Am. J. Obstet. Gynecol.,164:669-674, 1991.
Berchuck et al., “Overexpression of HER-2
euis associated with poor survival in advanced epithelial ovarian cancer,”Cancer Res.,50:4087-4091, 1990.
Berchuck et al., “Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β,”Am. J. Obstet. Gynecol.,166:676-684, 1992.
Berchuck et al., “The p53 tumor suppressor gene frequently is altered in gynecologic cancers,”Am. J. Obstet. Gynecol.,170:246-252, 1994.
Feig et al., “Somatic activation of RasK gene in a human ovarian carcinoma,”Science,223:698-700, 1984.
Havrilesky et al., “Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor-β”Cancer Res.,55:944-948, 1995.
Hoggard et al., “Allelic imbalance on chromosome 1 in human breast cancer. II. Microsatellite repeat analysis,”Genes, Chromosome Cancer,12:24-31, 1995.
Hurteau et al., “Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites,”Cancer,74:93-99, 1994.
Jacobs et al., “A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus,”Cancer Res.,53:1218-1221, 1993.
Jacobs et al., “Clonal origin of epithelial ovarian cancer: Analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation,”J. Natl. Cancer Inst.,84:1793-1798, 1992.
Kacinski et al., “Neu protein overexpression in benign, borderline, and malignant ovarian neoplasms,”Gynecol. Oncol.,44:245-253, 1992.
Karlan et al., “Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation,”Gyn. Onc,59(1):67-74, 1995.
Kitayama et al., “A Ras-related gene with transformation suppressor activity,”Cell,56:77-84, 1989.
Kohler et al., “Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer,”J. Natl. Cancer Inst.,85:1513-1519, 1993.
Li et al., “Advanced ovarian carcinoma: molecular evidence of unifocal origin,”Gyn. Onc.,51(1):21-25, 1993.
Lidor et al., “Constitutive production of macrophage colony stimulating factor and interleukin-6 by human ovarian surface epithelial cells,”Exp. Cell Res.,207:332-339, 1993.
Lidor et al., “Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer,”Int. J. Cancer,49(5):704-710, 1991.
Loupart et al., “Allelic imbalance on chromosome 1 in human breast cancer. 1. Ministellite and RFLP analysis,”Genes Chromosomes Cancer,12:16-23, 1995.
Lynch et al., “Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome),”Int. J. Cancer,69(1):38-43, 1996.
Malkin et al., “Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms,”Science,250:1233-1238, 1990.
Miki et al., “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1,”Science,266:66-71, 1994.
Mok et al., “Unifocal origin of advanced human epithelial ovarian cancers,”Cancer Res.,52:5119-5122, 1992.
Morishige et al., “Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in ovarian cancer cell line in vitro,”Cancer Res.,51(21):5951-5955, 1991.
Moser et al., “Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinomas,”Int J. Cancer,56:552-559, 1994.
Nagai et al., “Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer,”Cancer Res.,55:1752-1757, 1995.
Rodriguez et al., “Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor”Am. J. Obstet. Gynecol.,164:745-750, 1991.
Rubin et al., “Prognostic significance of HER-2
eu expression in advanced ovarian cancer,”Am. J. Obstet. Gynecol.,168:162-169, 1993.
Shultz et al., “Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene,”Cell,73(7):1445-1454, 1993.
Stromberg et al., “Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines,”Cancer Res.,52(2):341-347, 1992.
Wiener et al., “Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas,”Am. J. Obstet. Gynecol.,170:1177-1183, 1994.
Wiener et al., “Transfection of human ovarian cancer cells with the HER-2
eureceptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, and PTP- expression,”Gynecol. Oncol.,61:223-240, 1996.
Wooster et al., “Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13,”Science,265:2088-2090, 1994.
Worsley et al., “Overexpression of cyclin D1 in epithelial ovarian cancers,”Gynecol. Oncol.,64:189-195, 1997.
Wu et al., “Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha,”Am. J. Obstet. Gynecol.,166:997-1007, 1992.
Xu et al., “Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells,”Cancer Res.,51:4012-4019, 1991.
Xu et al., “Heregulin and anti-p185c-erbB-2antibodies inhibit proliferation, increase invasiveness and enhance tyrosine autophosphorylation of breast cancer cells that overexpress p185c-erbB-2:Increased invasiveness may contribute to poor prognosis,”Clin. Cancer Res.,3:1629-1634, 1997.
Xu et al., “Increased serum levels of macrophage colony-stimulating factor in ovarian cancer,”Am. J. Obstet. Gynecol.,165:1356-1362, 1991.
Xu et al., “The outcome of Heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression,”Clin. Cancer Res.,5:3653-3660, 1999.
Yu et al., “Expression of a murine cytomegalovirus early and late protein in latently infected mice,”J. Infectious Diseases,172:371-379, 1995.
Yu et al., “Liposome-mediatedin vivoE1A gene transfer suppressed dissemination of
Bast, Jr. Robert C.
Xu Fengji
Yu Yinhua
Board of Regents the University of Texas System
Fulbright & Jaworski L.L.P.
Nickol Gary B.
LandOfFree
NOEY2 gene compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NOEY2 gene compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NOEY2 gene compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861023